The additive bronchodilating effect of isoproterenol-phenylephrine aerosol following ipratropium bromide was examinedin seven intrinsic asthmatic patients and seven chronic bronchitic patients. FVC, FEVj and Zrs were measured before and 30 min. after inhalation of ipratropium, 40 jug. Then inhalation of isoproterenol, 600 /ig and phenylephrine, 570 jug was added and the pulmonary functions were measured 30 min. later. The age, baseline values of FVCand FEV\, and the increases in FEVj and 1/Zrs with ipratropium did not differ between the two. Isoproterenol-phenylephrine aerosol following ipratropium produced further increases in FEVj and 1/Zrs in asthmatic patients but no additive increases in bronchitic patients. These findings indicate that the role of autonomicnervous system, especially adrenergic system, on airway obstruction maybe different between asthmatic and bronchitic patients arid the method applied in this study may be helpful in differentiating these airway disorders.
system . But it has not been knownhow the relation between these autonomic nervous systems is altered in humans with airway obstruction. were encouraged to report any side effects. Statistical analyses were performed using a two-tailed student's t-test for paired data ' and the Mann-Whitney U testlo).
RESULTS
Baseline values of FVC and FEVi showed no difference between asthmatic and bronchitic patients (Table 1) . However, the mean value of Zrs 2), and the second inhalation of isoproterenolphynylephrine produced further, statistically significant, improvements in these measurements (p <0.05in
FEVi, Fig. 1,p<0 .05inZrs, Fig. 2 ). In patients with chronic bronchitis, the first inhalation of ipratropium produced significant improvements in FEVi (p^0.01, Fig. 1 ) and Zrs (p <C 0.01, Fig. 2 ). However, the second inhalation of isoproterenol-phynylephrine did not produce any moreimprovementsin these parameters.
In the groups with asthma and bronchitis, the mean values of FVCincreased with the first inhalation of ipratoropium and additionally increased was not significant. In the asthmatic group, the total percent increase in FEVi (22.0 ± 3.1%) after Fig. 4 . Mean percent increases in FVC, FEV\ and 1/Zrs before and after inhalation of ipratropium bromide followed by isoproterenol-phenylephrine in seven patients with intrinsic asthma (BA) and seven patients with chronic bronchitis (CB). The bars indicate standard error (S.E.). IB = after inhalation of ipratropium bromide Iso = after inhalation of isoproterenol-phenylephrine following ipratropium bromide NS = insignificant difference sol was used as an adrenergic agent because it is available for the treatment of asthama as well as selective /^-adrenergic stimulants, such as salbutamol aerosol, and has fewer side effects than isoproterenol alone. Our preliminary study in normal subjects
showed that the degrees of increases in FEVi and 1/Zrs following isoproterenolphenylephrine aerosol were not different from those following isoproterenol aerosol, and that rash and palpitation occurred in one of nine and two of nine, respectively, after inhaling isoproterenol alone, while no side effect was observed after isoproterenol-phenylephrine aerosol. Astin ' showed that reversibility of airway obstruction to bronchodilators was proportional to the degree of initial airwasy obstruction. Ullah and his associates ' showedthat ipratropium was more effective in asthmatic patients aged over 40 than in younger patients. In this study, there were no differences in the ages or the baseline spirometric measurements between asthmatic and bronchitic patients.
To our knowledge, no previous study has ever been performed on the effects of anticholinergic and adrenergic agents on airway obstruction in older patients with intrinsic asthma compared to age-matched subjects with chronic bronchitis.
Previous studies ' ' have shown that bronchodilating effect of ipratropium was not significantly different in asthmatic patients and those with bronchitis and our data showed similar results in older subjects with these conditions. Lightbody and his associates ' reported that the combination of ipratropium and salbutamol produced much greater increase in FEVi than did either alone, but the bronchodilating effect of the combination was not different in asthmatic patients aged 13 to 60 years (mean, 36.5) and bronchitic patients aged 38 to 70 years (mean, 52.0).
In contrast, the addition of isoproterenolphenylephrine aerosol produced further bronchodilation than did ipratropium alone in patients with asthma, but did not produce any changes in patients with bronchitis, in this study. In our preliminary study, the additive bronchodilating effect of isoproterenol-phenylephrine aerosol was not different from that of isoproterenol alone in normal subjects and that of Salbutamol in asth-matic and bronchitic patients. Therefore, it is unlikely that the discrepancy between our findings and those of Lightbody et al is due to phenylephrine. It would, however, in part, depend on the degree of the reversibility of airways obstruction, because chronic bronchitic patients with reversible airway narrowing were selected as the bronchitic subjects in Lightbody's studyll. Hughes and his associated13^showed that the increase in FEVi with a combination of fenoterol and ipratropium was not different from that with ipratropium alone in pulmonary emphysema.
In conclusion, the relation between cholinergic and adrenergic systems on airwasy obstruction in older patients with intrinsic asthma may be different from that in subjects of similar ages with chronic bronchitis because additive bronchodilating effect of inhaling adrenergic agents on airways pretreated with anticholinergic drugs was observed in asthmatic patients, but not in bronchitic patients. The method applied in this study might be useful as a screening test by which asthma could be differentiated from chronic bronchitis or pulmonary emphysema.
